Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subset of Hodgkin lymphoma (HL). It has a distinct clinical and pathological presentation. Unlike classic HL, where the predominant malignant cells are Reed Sternberg cells, the malignant cells in NLPHL are known as lymphocyte predomi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-07-01
|
| Series: | Journal of Investigative Medicine High Impact Case Reports |
| Online Access: | https://doi.org/10.1177/23247096221111767 |
| _version_ | 1818189179423555584 |
|---|---|
| author | Adarsh Sidda MD Nikolas Kristopher Naleid MD Gurusidda Manu MD Vincent Graffeo MD Muhammad Omer Jamil MD |
| author_facet | Adarsh Sidda MD Nikolas Kristopher Naleid MD Gurusidda Manu MD Vincent Graffeo MD Muhammad Omer Jamil MD |
| author_sort | Adarsh Sidda MD |
| collection | DOAJ |
| description | Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subset of Hodgkin lymphoma (HL). It has a distinct clinical and pathological presentation. Unlike classic HL, where the predominant malignant cells are Reed Sternberg cells, the malignant cells in NLPHL are known as lymphocyte predominant (LP) cells, with their own unique immunohistochemistry antigen expression and staining pattern. Based on risk stratification and staging of the disease, treatment can range from active surveillance in asymptomatic patients with no organ compromise or bulky disease, to aggressive chemotherapeutic agents in advanced disease. Guidelines on which of these chemotherapy regimens would offer the most benefit to our patients are limited due to lack of randomized-controlled studies. Majority of the current prospective data on treatment were inclusive of both HL and NLPHL. Thus, the regimens employed in treatment of NLPHL are similar to the ones used in HL, though NLPHL is often viewed as its own distinct entity. This article aims to review the current literature and future advances on treatment of this rare disease. |
| first_indexed | 2024-12-11T23:38:42Z |
| format | Article |
| id | doaj.art-663752d395534abeacc0ec911008e4e1 |
| institution | Directory Open Access Journal |
| issn | 2324-7096 |
| language | English |
| last_indexed | 2024-12-11T23:38:42Z |
| publishDate | 2022-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Investigative Medicine High Impact Case Reports |
| spelling | doaj.art-663752d395534abeacc0ec911008e4e12022-12-22T00:45:47ZengSAGE PublishingJournal of Investigative Medicine High Impact Case Reports2324-70962022-07-011010.1177/23247096221111767Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case DiscussionAdarsh Sidda MD0Nikolas Kristopher Naleid MD1Gurusidda Manu MD2Vincent Graffeo MD3Muhammad Omer Jamil MD4Department of Hematology & Oncology, Marshall University, Huntington, WV, USASchool of Medicine, California University of Science and Medicine, Colton, USAInternal Medicine, University of Texas Southwestern, Dallas, USADepartment of Pathology, Marshall University, Huntington, WV, USADepartment of Hematology & Oncology, Marshall University, Huntington, WV, USANodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subset of Hodgkin lymphoma (HL). It has a distinct clinical and pathological presentation. Unlike classic HL, where the predominant malignant cells are Reed Sternberg cells, the malignant cells in NLPHL are known as lymphocyte predominant (LP) cells, with their own unique immunohistochemistry antigen expression and staining pattern. Based on risk stratification and staging of the disease, treatment can range from active surveillance in asymptomatic patients with no organ compromise or bulky disease, to aggressive chemotherapeutic agents in advanced disease. Guidelines on which of these chemotherapy regimens would offer the most benefit to our patients are limited due to lack of randomized-controlled studies. Majority of the current prospective data on treatment were inclusive of both HL and NLPHL. Thus, the regimens employed in treatment of NLPHL are similar to the ones used in HL, though NLPHL is often viewed as its own distinct entity. This article aims to review the current literature and future advances on treatment of this rare disease.https://doi.org/10.1177/23247096221111767 |
| spellingShingle | Adarsh Sidda MD Nikolas Kristopher Naleid MD Gurusidda Manu MD Vincent Graffeo MD Muhammad Omer Jamil MD Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion Journal of Investigative Medicine High Impact Case Reports |
| title | Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion |
| title_full | Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion |
| title_fullStr | Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion |
| title_full_unstemmed | Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion |
| title_short | Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion |
| title_sort | nodular lymphocyte predominant hodgkin lymphoma review of current literature and case discussion |
| url | https://doi.org/10.1177/23247096221111767 |
| work_keys_str_mv | AT adarshsiddamd nodularlymphocytepredominanthodgkinlymphomareviewofcurrentliteratureandcasediscussion AT nikolaskristophernaleidmd nodularlymphocytepredominanthodgkinlymphomareviewofcurrentliteratureandcasediscussion AT gurusiddamanumd nodularlymphocytepredominanthodgkinlymphomareviewofcurrentliteratureandcasediscussion AT vincentgraffeomd nodularlymphocytepredominanthodgkinlymphomareviewofcurrentliteratureandcasediscussion AT muhammadomerjamilmd nodularlymphocytepredominanthodgkinlymphomareviewofcurrentliteratureandcasediscussion |